Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis

Lung Cancer

Volumn 85, Issue 3, 2014, Pages 479-480

  Lin, Chou Han ^a   Lin, Ming Tzer ^a   Kuo, Yao Wen ^b   Ho, Chao Chi ^b  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Afatinib; Cetuximab; EGFR; Leptomeningeal carcinomatosis; Non small cell lung cancer; Tyrosine kinase inhibitor

Indexed keywords

AFATINIB; BEVACIZUMAB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ADULT; ANISOCORIA; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOMATOUS MENINGITIS; CASE REPORT; CYTOLOGY; DISEASE COURSE; DRUG MEGADOSE; DRUG PULSE THERAPY; DYSPNEA; FEMALE; HEADACHE; HUMAN; LUNG ADENOCARCINOMA; NEUROIMAGING; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEURA EFFUSION; PRIORITY JOURNAL; TREATMENT RESPONSE; ADENOCARCINOMA; BRAIN; FATALITY; GENETICS; LUNG NEOPLASMS; MENINGEAL CARCINOMATOSIS; MENINGEAL NEOPLASMS; MUTATION; NEOPLASMS, SECOND PRIMARY; PATHOLOGY; SECONDARY;

ADENOCARCINOMA; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN; FATAL OUTCOME; FEMALE; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MENINGEAL CARCINOMATOSIS; MENINGEAL NEOPLASMS; MUTATION; NEOPLASMS, SECOND PRIMARY; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84926420126     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.06.002     Document Type: Article

References (10)

1. Lee S.J., Lee J.I., Nam D.H., Ahn Y.C., Han J.H., Sun J.M., et al. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol 2013, 8:185-191.
2. Morris P.G., Reiner A.S., Szenberg O.R., Clarke J.L., Panageas K.S., Perez H.R., et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol. 2012, 7:382-385.
3. Umemura S., Tsubouchi K., Yoshioka H., Hotta K., Takigawa N., Fujiwara K., et al. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer 2012, 77:134-139.
4. Grommes C., Oxnard G.R., Kris M.G., Miller V.A., Pao W., Holodny A.I., et al. Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 2011, 13:1364-1369.
5. Miller V.A., Hirsh V., Cadranel J., Chen Y.M., Park K., Kim S.W., et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012, 13:528-538.
6. Regales L., Gong Y., Shen R., de Stanchina E., Vivanco I., Goel A., et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009, 119:3000-3010.
7. Horn L, Groen H, Smit E, Janjigian Y, Fu Y, Wang F, et al. Activity and tolerability of combined EGFR targeting with afatinib (BIBW 2992) and cetuximab in T790M+ NSCLC patients. Presented at the 14th World Conference on Lung Cancer, July 3-7, 2011, Amsterdam, the Netherlands. (abstr O19.07).
8. Janjigian Y., Groen H., Horn L., Smit E., Fu Y., Wang F., et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol 2011, Suppl. 29:482s. abstr 7525.
9. Yap T.A., Vidal L., Adam J., Stephens P., Spicer J., Shaw H., et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010, 28:3965-3972.
10. Rades D., Nadrowitz R., Buchmann I., Hunold P., Noack F., Schild S.E., et al. Radiolabeled cetuximab plus whole-brain irradiation (WBI) for the treatment of brain metastases from non-small cell lung cancer (NSCLC). Strahlenther Onkol 2010, 186:458-462.